Today: 20 March 2026
Subscribe
Browse Category

ASX:CSL 24 December 2025 - 26 January 2026

CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

CSL share price rises on ASX as U.S. vaccine policy shifts rattle the sector

CSL Ltd shares closed 0.7% higher at A$179.62 Friday, extending Thursday’s gains, with 1.01 million shares traded. The stock’s rise comes as U.S. vaccine policy changes under Health Secretary Robert F. Kennedy Jr. weigh on sentiment for CSL’s Seqirus unit. CSL delayed a Seqirus spinoff and cut its 2026 growth forecast in October, citing falling U.S. flu vaccination rates. Half-year results are due Feb. 11.
23 January 2026
···
CSL share price slips after close as RBC upgrade turns focus to Feb. 11 results

CSL share price slips after close as RBC upgrade turns focus to Feb. 11 results

CSL shares closed down 0.33% at A$176.11 on Wednesday, staying well below last year’s highs. RBC Capital upgraded CSL to “Outperform” and raised its price target to A$230, citing valuation upside despite weak U.S. flu vaccine demand. Investors are focused on CSL’s half-year results and interim dividend due Feb. 11. The S&P/ASX 200 slipped 0.37% amid broader market volatility.
21 January 2026
··
CSL share price edges up after RBC upgrade as investors eye February results

CSL share price edges up after RBC upgrade as investors eye February results

CSL shares rose 0.1% to A$176.70 Tuesday after RBC Capital Markets upgraded the stock, despite the ASX 200 falling 0.66%. The move follows a 36% drop in CSL’s share price over the past year and comes ahead of its Feb. 11 half-year results. RBC cited competition and weak flu vaccine demand as near-term risks. CSL last cut its 2026 revenue and profit growth forecasts in October and delayed its Seqirus spin-off.
20 January 2026
·
CSL share price slips after ASX close: what investors watch next for ASX:CSL ahead of February results

CSL share price slips after ASX close: what investors watch next for ASX:CSL ahead of February results

CSL Ltd shares fell 1.0% to A$173.32 Tuesday, underperforming the S&P/ASX 200, which rose 0.56%. The drop follows last year’s cut to CSL’s FY26 forecasts and a delay to the Seqirus spin-off after a sharp decline in U.S. flu vaccinations. No new company updates were released Tuesday. CSL’s next scheduled disclosure is its half-year results on Feb. 11.
13 January 2026
···
CSL Limited (ASX:CSL) Stock Update on 24 December 2025: Share Price Drops, Buyback Progress, Seqirus Uncertainty, and 2026 Analyst Forecasts

CSL Limited (ASX:CSL) Stock Update on 24 December 2025: Share Price Drops, Buyback Progress, Seqirus Uncertainty, and 2026 Analyst Forecasts

CSL Limited shares closed at A$171.48 on 24 December 2025, down 2.38%, near their 52-week low of A$168.00. The company delayed the spin-off of its Seqirus vaccine arm and cut its FY26 outlook after a sharper-than-expected drop in US flu vaccination rates. Market value stands at about A$85.5 billion. Shares are down roughly 39% over the past year.
24 December 2025
·
1 2 3 4

Stock Market Today

  • European Stocks Rise as Oil Prices Drop and Rate Hike Bets Grow
    March 20, 2026, 5:11 AM EDT. European stocks rebounded on Friday, led by banking and construction sectors, as oil prices eased from recent highs above $119 a barrel. The decline followed U.S. signals about possibly lifting sanctions on Iranian crude to reduce energy costs. Central banks across Europe, including the European Central Bank (ECB) and Bank of England (BoE), held interest rates steady amid uncertainty from the U.S.-Iran conflict but traders increased bets on further rate hikes later this year. The ECB highlighted inflation risks tied to the war, while the BoE's unanimous hold hinted at readiness to act. Meanwhile, Unilever disclosed talks to sell part of its foods business to McCormick & Company, adding corporate activity amid market shifts.
Go toTop